Pfizer’s Lyrica (pregabalin) failed to meet the primary endpoint in a phase 3 trial evaluating it as an adjunctive therapy for epilepsy patients with primary generalized tonic-clonic (PGTC) seizures.
OncoSec Medical, a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, announced that the first patient has been dosed in TRIFECTA, a triple combination clinical trial of OncoSec's TAVO, an IDO1 drug (epacadostat) and KEYTRUDA in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer.
Novartis said that IND/GLY/MF (QVM149), a new inhaled combination treatment, showed significant improvements over current standard-of-care inhaled treatment and placebo in two phase 2 trials in patients with asthma.
In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease.
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase inhibitor, in adult patients with progressing desmoid tumors.
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.
AbbVie has discontinued an ongoing phase 3 trial evaluating its antibody drug conjugate (ADC) depatuxizumab mafodotin (Depatux-M) for the treatment of newly diagnosed glioblastoma (GBM), an aggressive type of brain cancer, owing to futility.
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Melior Pharmaceuticals I, a US-based mid-stage biopharma company, said that its insulin sensitizer, tolimidone (MLR-1023) has succeeded in a phase 2b trial in Type 2 diabetes mellitus (T2DM).
Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced positive results of an ex-U.S. proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.